Journal of Genetic Medicine

  • 제14권2호
  • /
  • Pages.49-55
  • /
  • 2017
  • /
  • 1226-1769(pISSN)
  • /
  • 2383-8442(eISSN)
대한의학유전학회 (Korean Society of Medical Genetics and Genomics)
권호 표지
DOI QR코드

DOI QR Code

Biomarkers and genetic factors for early prediction of pre-eclampsia

  • Kim, Hannah (Department of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University) ;
  • Shim, Sung Shin (Department of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University)
  • 투고 : 2017.11.10
  • 심사 : 2017.12.15
  • 발행 : 2017.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Pre-eclampsia is known to cause considerable maternal morbidity and mortality. Thus, many studies have examined the etiopathogenesis of pre-eclampsia. While many pathophysiological factors related to pre-eclampsia have been identified, the precise etiopathogenesis of pre-eclampsia remains unclear. Numerous studies have identified factors for the early prediction for pre-eclampsia to lead to preparation and closer observation on pre-eclampsia when it occurs. This article reviews on current studies of biomarkers and genetic factors related to pre-eclampsia, which may be important for developing strategies for early prediction of pre-eclampsia.

키워드

참고문헌

  1. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009;33:130-7. https://doi.org/10.1053/j.semperi.2009.02.010
  2. Spencer-Jones J. Make every mother and child count. S Afr Med J 2005;95:382, 384.
  3. Lyons G. Saving mothers'lives: confidential enquiry into maternal and child health 2003-5. Int J Obstet Anesth 2008;17:103-5. https://doi.org/10.1016/j.ijoa.2008.01.006
  4. Warrington JP, George EM, Palei AC, Spradley FT, Granger JP. Recent advances in the understanding of the pathophysiology of preeclampsia. Hypertension 2013;62:666-73. https://doi.org/10.1161/HYPERTENSIONAHA.113.00588
  5. Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ 2001;323:1213-7. https://doi.org/10.1136/bmj.323.7323.1213
  6. Yu CK, Khouri O, Onwudiwe N, Spiliopoulos Y, Nicolaides KH; Fetal Medicine Foundation Second-Trimester Screening Group. Prediction of pre-eclampsia by uterine artery Doppler imaging: relationship to gestational age at delivery and small-for-gestational age. Ultrasound Obstet Gynecol 2008;31:310-3. https://doi.org/10.1002/uog.5252
  7. Witlin AG, Saade GR, Mattar F, Sibai BM. Predictors of neonatal outcome in women with severe pre-eclampsia or eclampsia between 24 and 33 weeks' gestation. Am J Obstet Gynecol 2000;182:607-11. https://doi.org/10.1067/mob.2000.104224
  8. Thilaganathan B, Wormald B, Zanardini C, Sheldon J, Ralph E, Papageorghiou AT. Early-pregnancy multiple serum markers and secondtrimester uterine artery Doppler in predicting preeclampsia. Obstet Gynecol 2010;115:1233-8. https://doi.org/10.1097/AOG.0b013e3181dd5137
  9. Zhong Y, Tuuli M, Odibo AO. First-trimester assessment of placenta function and the prediction of preeclampsia and intrauterine growth restriction. Prenat Diagn 2010;30:293-308.
  10. Scazzocchio E, Figueras F. Contemporary prediction of preeclampsia. Curr Opin Obstet Gynecol 2011;23:65-71. https://doi.org/10.1097/GCO.0b013e328344579c
  11. Cuckle HS. Screening for pre-eclampsia--lessons from aneuploidy screening. Placenta 2011;32 Suppl:S42-8. https://doi.org/10.1016/j.placenta.2010.07.015
  12. Nicolaides KH, Bindra R, Turan OM, Chefetz I, Sammar M, Meiri H, et al. A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obstet Gynecol 2006;27:13-7.
  13. Anderson UD, Gram M, Jalmby M, Kerstrom B, Hansson SR. [167-POS] : The human endogenous protection system against cell-free hemoglobin is overwhelmed during preeclampsia - New biomarkers and potential targets for therapy. Pregnancy Hypertens 2015;5:86.
  14. Tjwa M, Luttun A, Autiero M, Carmeliet P. VEGF and PlGF: two pleiotropic growth factors with distinct roles in development and homeostasis. Cell Tissue Res 2003;314:5-14. https://doi.org/10.1007/s00441-003-0776-3
  15. Tsiakkas A, Duvdevani N, Wright A, Wright D, Nicolaides KH. Serum placental growth factor in the three trimesters of pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol 2015;45:591-8. https://doi.org/10.1002/uog.14811
  16. Kar M. Role of biomarkers in early detection of preeclampsia. J Clin Diagn Res 2014;8:BE01-4.
  17. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672-83. https://doi.org/10.1056/NEJMoa031884
  18. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-58. https://doi.org/10.1172/JCI17189
  19. Park HJ, Kim SH, Jung YW, Shim SS, Kim JY, Cho YK, et al. Screening models using multiple markers for early detection of late-onset preeclampsia in low-risk pregnancy. BMC Pregnancy Childbirth 2014;14:35. https://doi.org/10.1186/1471-2393-14-35
  20. Lawrence JB, Oxvig C, Overgaard MT, Sottrup-Jensen L, Gleich GJ, Hays LG, et al. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci U S A 1999;96:3149-53. https://doi.org/10.1073/pnas.96.6.3149
  21. Deveci K, Sogut E, Evliyaoglu O, Duras N. Pregnancy-associated plasma protein-A and C-reactive protein levels in pre-eclamptic and normotensive pregnant women at third trimester. J Obstet Gynaecol Res 2009;35:94-8. https://doi.org/10.1111/j.1447-0756.2008.00835.x
  22. Bersinger NA, Odegard RA. Second- and third-trimester serum levels of placental proteins in preeclampsia and small-for-gestational age pregnancies. Acta Obstet Gynecol Scand 2004;83:37-45. https://doi.org/10.1111/j.1600-0412.2004.00277.x
  23. Bersinger NA, Smarason AK, Muttukrishna S, Groome NP, Redman CW. Women with preeclampsia have increased serum levels of pregnancy- associated plasma protein A (PAPP-A), inhibin A, activin A and soluble E-selectin. Hypertens Pregnancy 2003;22:45-55. https://doi.org/10.1081/PRG-120016794
  24. Smith GC, Stenhouse EJ, Crossley JA, Aitken DA, Cameron AD, Connor JM. Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab 2002;87:1762-7. https://doi.org/10.1210/jcem.87.4.8430
  25. Poon LC, Akolekar R, Lachmann R, Beta J, Nicolaides KH. Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11-13 weeks. Ultrasound Obstet Gynecol 2010;35:662-70.
  26. Muttukrishna S, North RA, Morris J, Schellenberg JC, Taylor RS, Asselin J, et al. Serum inhibin A and activin A are elevated prior to the onset of pre-eclampsia. Hum Reprod 2000;15:1640-5. https://doi.org/10.1093/humrep/15.7.1640
  27. Kang JH, Farina A, Park JH, Kim SH, Kim JY, Rizzo N, et al. Down syndrome biochemical markers and screening for preeclampsia at first and second trimester: correlation with the week of onset and the severity. Prenat Diagn 2008;28:704-9. https://doi.org/10.1002/pd.1997
  28. Ree PH, Hahn WB, Chang SW, Jung SH, Kang JH, Cha DH, et al. Early detection of preeclampsia using inhibin a and other second-trimester serum markers. Fetal Diagn Ther 2011;29:280-6. https://doi.org/10.1159/000322742
  29. Sibai BM, Koch MA, Freire S, Pinto e Silva JL, Rudge MV, Martins- Costa S, et al. Serum inhibin A and angiogenic factor levels in pregnancies with previous preeclampsia and/or chronic hypertension: are they useful markers for prediction of subsequent preeclampsia? Am J Obstet Gynecol 2008;199:268.e1-9. https://doi.org/10.1016/j.ajog.2008.06.071
  30. Than NG, Romero R, Goodman M, Weckle A, Xing J, Dong Z, et al. A primate subfamily of galectins expressed at the maternal-fetal interface that promote immune cell death. Proc Natl Acad Sci U S A 2009;106:9731-6. https://doi.org/10.1073/pnas.0903568106
  31. Than NG, Romero R, Kim CJ, McGowen MR, Papp Z, Wildman DE. Galectins: guardians of eutherian pregnancy at the maternal-fetal interface. Trends Endocrinol Metab 2012;23:23-31. https://doi.org/10.1016/j.tem.2011.09.003
  32. Huppertz B. Placental origins of preeclampsia: challenging the current hypothesis. Hypertension 2008;51:970-5. https://doi.org/10.1161/HYPERTENSIONAHA.107.107607
  33. Huppertz B, Sammar M, Chefetz I, Neumaier-Wagner P, Bartz C, Meiri H. Longitudinal determination of serum placental protein 13 during development of preeclampsia. Fetal Diagn Ther 2008;24:230-6. https://doi.org/10.1159/000151344
  34. Gonen R, Shahar R, Grimpel YI, Chefetz I, Sammar M, Meiri H, et al. Placental protein 13 as an early marker for pre-eclampsia: a prospective longitudinal study. BJOG 2008;115:1465-72. https://doi.org/10.1111/j.1471-0528.2008.01902.x
  35. Grubb AO. Cystatin C--properties and use as diagnostic marker. Adv Clin Chem 2000;35:63-99.
  36. Kristensen K, Larsson I, Hansson SR. Increased cystatin C expression in the pre-eclamptic placenta. Mol Hum Reprod 2007;13:189-95. https://doi.org/10.1093/molehr/gal111
  37. Thilaganathan B, Ralph E, Papageorghiou AT, Melchiorre K, Sheldon J. Raised maternal serum cystatin C: an early pregnancy marker for preeclampsia. Reprod Sci 2009;16:788-93. https://doi.org/10.1177/1933719109336618
  38. Souza DG, Soares AC, Pinho V, Torloni H, Reis LF, Teixeira MM, et al. Increased mortality and inflammation in tumor necrosis factorstimulated gene-14 transgenic mice after ischemia and reperfusion injury. Am J Pathol 2002;160:1755-65. https://doi.org/10.1016/S0002-9440(10)61122-4
  39. Cetin I, Cozzi V, Pasqualini F, Nebuloni M, Garlanda C, Vago L, et al. Elevated maternal levels of the long pentraxin 3 (PTX3) in preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol 2006;194:1347-53. https://doi.org/10.1016/j.ajog.2005.11.018
  40. Andre P. P-selectin in haemostasis. Br J Haematol 2004;126:298-306. https://doi.org/10.1111/j.1365-2141.2004.05032.x
  41. Polgar J, Matuskova J, Wagner DD. The P-selectin, tissue factor, coagulation triad. J Thromb Haemost 2005;3:1590-6. https://doi.org/10.1111/j.1538-7836.2005.01373.x
  42. Holthe MR, Staff AC, Berge LN, Lyberg T. Different levels of platelet activation in preeclamptic, normotensive pregnant, and nonpregnant women. Am J Obstet Gynecol 2004;190:1128-34. https://doi.org/10.1016/j.ajog.2003.10.699
  43. Konijnenberg A, Stokkers EW, van der Post JA, Schaap MC, Boer K, Bleker OP, et al. Extensive platelet activation in preeclampsia compared with normal pregnancy: enhanced expression of cell adhesion molecules. Am J Obstet Gynecol 1997;176:461-9. https://doi.org/10.1016/S0002-9378(97)70516-7
  44. Yoneyama Y, Suzuki S, Sawa R, Kiyokawa Y, Power GG, Araki T. Plasma adenosine levels and P-selectin expression on platelets in preeclampsia. Obstet Gynecol 2001;97:366-70.
  45. Dunlop LC, Skinner MP, Bendall LJ, Favaloro EJ, Castaldi PA, Gorman JJ, et al. Characterization of GMP-140 (P-selectin) as a circulating plasma protein. J Exp Med 1992;175:1147-50. https://doi.org/10.1084/jem.175.4.1147
  46. Bretelle F, Sabatier F, Desprez D, Camoin L, Grunebaum L, Combes V, et al. Circulating microparticles: a marker of procoagulant state in normal pregnancy and pregnancy complicated by preeclampsia or intrauterine growth restriction. Thromb Haemost 2003;89:486-92. https://doi.org/10.1055/s-0037-1613378
  47. Lok CA, Nieuwland R, Sturk A, Hau CM, Boer K, Vanbavel E, et al. Microparticle-associated P-selectin reflects platelet activation in preeclampsia. Platelets 2007;18:68-72. https://doi.org/10.1080/09537100600864285
  48. Nasrollahi S, Hoseini Panah SM, Tavilani H, Tavasoli S, Naderan M, Shoar S. Antioxidant status and serum levels of selectins in preeclampsia. J Obstet Gynaecol 2015;35:16-8. https://doi.org/10.3109/01443615.2014.935710
  49. Fong FM, Sahemey MK, Hamedi G, Eyitayo R, Yates D, Kuan V, et al. Maternal genotype and severe preeclampsia: a HuGE review. Am J Epidemiol 2014;180:335-45. https://doi.org/10.1093/aje/kwu151
  50. Buurma AJ, Turner RJ, Driessen JH, Mooyaart AL, Schoones JW, Bruijn JA, et al. Genetic variants in pre-eclampsia: a meta-analysis. Hum Reprod Update 2013;19:289-303. https://doi.org/10.1093/humupd/dms060
  51. Isaacs A, Cox RA, Rotem Z. Foreign nucleic acids as the stimulus to make interferon. Lancet 1963;2:113-6.
  52. Scharfe-Nugent A, Corr SC, Carpenter SB, Keogh L, Doyle B, Martin C, et al. TLR9 provokes inflammation in response to fetal DNA: mechanism for fetal loss in preterm birth and preeclampsia. J Immunol 2012;188:5706-12. https://doi.org/10.4049/jimmunol.1103454
  53. Miranda ML, Macher HC, Munoz-Hernandez R, Vallejo-Vaz A, Moreno-Luna R, Villar J, et al. Role of circulating cell-free DNA levels in patients with severe preeclampsia and HELLP syndrome. Am J Hypertens 2013;26:1377-80. https://doi.org/10.1093/ajh/hpt187
  54. Tjoa ML, Cindrova-Davies T, Spasic-Boskovic O, Bianchi DW, Burton GJ. Trophoblastic oxidative stress and the release of cell-free fetoplacental DNA. Am J Pathol 2006;169:400-4. https://doi.org/10.2353/ajpath.2006.060161
  55. Lo YM, Leung TN, Tein MS, Sargent IL, Zhang J, Lau TK, et al. Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia. Clin Chem 1999;45:184-8.
  56. Grill S, Rusterholz C, Zanetti-Dallenbach R, Tercanli S, Holzgreve W, Hahn S, et al. Potential markers of preeclampsia--a review. Reprod Biol Endocrinol 2009;7:70. https://doi.org/10.1186/1477-7827-7-70
  57. Martin A, Krishna I, Badell M, Samuel A. Can the quantity of cell-free fetal DNA predict preeclampsia: a systematic review. Prenat Diagn 2014;34:685-91.
  58. Alvarez-Garcia I, Miska EA. MicroRNA functions in animal development and human disease. Development 2005;132:4653-62. https://doi.org/10.1242/dev.02073
  59. Enquobahrie DA, Abetew DF, Sorensen TK, Willoughby D, Chidambaram K, Williams MA. Placental microRNA expression in pregnancies complicated by preeclampsia. Am J Obstet Gynecol 2011;204:178.e12-21. https://doi.org/10.1016/j.ajog.2010.09.004
  60. Mayor-Lynn K, Toloubeydokhti T, Cruz AC, Chegini N. Expression profile of microRNAs and mRNAs in human placentas from pregnancies complicated by preeclampsia and preterm labor. Reprod Sci 2011;18:46-56. https://doi.org/10.1177/1933719110374115
  61. Wang W, Feng L, Zhang H, Hachy S, Satohisa S, Laurent LC, et al. Preeclampsia up-regulates angiogenesis-associated microRNA (i.e., miR-17, -20a, and -20b) that target ephrin-B2 and EPHB4 in human placenta. J Clin Endocrinol Metab 2012;97:E1051-9. https://doi.org/10.1210/jc.2011-3131
  62. Choi SY, Yun J, Lee OJ, Han HS, Yeo MK, Lee MA, et al. MicroRNA expression profiles in placenta with severe preeclampsia using a PNAbased microarray. Placenta 2013;34:799-804. https://doi.org/10.1016/j.placenta.2013.06.006
  63. Pineles BL, Romero R, Montenegro D, Tarca AL, Han YM, Kim YM, et al. Distinct subsets of microRNAs are expressed differentially in the human placentas of patients with preeclampsia. Am J Obstet Gynecol 2007;196:261.e1-6. https://doi.org/10.1016/j.ajog.2007.01.008
  64. Zhu XM, Han T, Sargent IL, Yin GW, Yao YQ. Differential expression profile of microRNAs in human placentas from preeclamptic pregnancies vs normal pregnancies. Am J Obstet Gynecol 2009;200:661.e1-7. https://doi.org/10.1016/j.ajog.2008.12.045
  65. Murphy MS, Casselman RC, Tayade C, Smith GN. Differential expression of plasma microRNA in preeclamptic patients at delivery and 1 year postpartum. Am J Obstet Gynecol 2015;213:367.e1-9. https://doi.org/10.1016/j.ajog.2015.05.013
  66. Hromadnikova I. Extracellular nucleic acids in maternal circulation as potential biomarkers for placental insufficiency. DNA Cell Biol 2012;31:1221-32. https://doi.org/10.1089/dna.2011.1530
  67. Hromadnikova I, Kotlabova K, Doucha J, Dlouha K, Krofta L. Absolute and relative quantification of placenta-specific micrornas in maternal circulation with placental insufficiency-related complications. J Mol Diagn 2012;14:160-7. https://doi.org/10.1016/j.jmoldx.2011.11.003
  68. Pan M, Ge Q, Li H, Yang Q, Lu J, Zhang D, et al. Sequencing the miRNAs in maternal plasma from women before and after parturition. J Nanosci Nanotechnol 2012;12:4035-43. https://doi.org/10.1166/jnn.2012.6196
  69. Chim SS, Shing TK, Hung EC, Leung TY, Lau TK, Chiu RW, et al. Detection and characterization of placental microRNAs in maternal plasma. Clin Chem 2008;54:482-90. https://doi.org/10.1373/clinchem.2007.097972
  70. Roberts JM, Bell MJ. If we know so much about preeclampsia, why haven't we cured the disease? J Reprod Immunol 2013;99:1-9. https://doi.org/10.1016/j.jri.2013.05.003